Exercise for Women With Peripheral Arterial Disease
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 60 - 100 |
| Updated: | 3/3/2019 |
| Start Date: | July 2009 |
| End Date: | February 2016 |
Hypothesis #1. Supervised exercise rehabilitation will result in greater increases in
exercise performance, peripheral vascular function, and health-related quality of life than
compared to the attention-control group.
Hypothesis #2. The change in peripheral vascular function will be predictive of improved
exercise performance following the supervised exercise program.
exercise performance, peripheral vascular function, and health-related quality of life than
compared to the attention-control group.
Hypothesis #2. The change in peripheral vascular function will be predictive of improved
exercise performance following the supervised exercise program.
Inclusion Criteria:
- women 60 years of age and older having a positive history of intermittent claudication
assessed by the San Diego Claudication Questionnaire
- exercise limited by intermittent claudication during a screening treadmill test using
the Gardner protocol
- an ankle/brachial index (ABI) < 0.90 at rest or < 0.73 immediately following the
treadmill exercise test
- at least one year past menopause
Exclusion Criteria:
- absence of PAD (peripheral artery disease)
- asymptomatic PAD (Fontaine stage I)
- rest pain due to PAD (Fontaine stage III)
- tissue loss due to PAD (Fontaine stage IV)
- medical conditions that are contraindicative for exercise according to the American
College of Sports Medicine (e.g., acute myocardial infarction, unstable angina, etc.)
- use of medications indicated for the treatment of intermittent claudication
(cilostazol and pentoxifylline) initiated within three months prior to investigation)
- cognitive dysfunction (mini-mental state examination score < 24)
- active cancer, renal disease, or liver disease
- a calf skin fold measurement > 50 mm, because of potential interference with the light
path of the near-infrared spectroscopy probe from penetrating the subcutaneous tissue
- pulse arterial oxygen saturation of the index finger < 95% because of the potential
deleterious effect on calf muscle StO2 from poor pulmonary gas exchange
We found this trial at
1
site
500 University Drive
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
Principal Investigator: Andrew W Gardner, PhD
Phone: 717-531-0003
Click here to add this to my saved trials
